AU2010262190B2 - Novel phenylimidazole derivative as PDE10A enzyme inhibitor - Google Patents

Novel phenylimidazole derivative as PDE10A enzyme inhibitor Download PDF

Info

Publication number
AU2010262190B2
AU2010262190B2 AU2010262190A AU2010262190A AU2010262190B2 AU 2010262190 B2 AU2010262190 B2 AU 2010262190B2 AU 2010262190 A AU2010262190 A AU 2010262190A AU 2010262190 A AU2010262190 A AU 2010262190A AU 2010262190 B2 AU2010262190 B2 AU 2010262190B2
Authority
AU
Australia
Prior art keywords
disorder
dementia
type
disease
bipolar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010262190A
Other languages
English (en)
Other versions
AU2010262190A1 (en
Inventor
Mohamed M. Farah
Jan Kehler
John Paul Kilburn
Morten Langgard
Jacob Nielsen
Andreas Ritzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2009/050134 external-priority patent/WO2009152825A1/en
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2010262190A1 publication Critical patent/AU2010262190A1/en
Application granted granted Critical
Publication of AU2010262190B2 publication Critical patent/AU2010262190B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010262190A 2009-06-19 2010-06-17 Novel phenylimidazole derivative as PDE10A enzyme inhibitor Ceased AU2010262190B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/DK2009/050134 2009-06-19
PCT/DK2009/050134 WO2009152825A1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors
PCT/DK2010/050147 WO2010145668A1 (en) 2009-06-19 2010-06-17 Novel phenylimidazole derivative as pde10a enzyme inhibitor

Publications (2)

Publication Number Publication Date
AU2010262190A1 AU2010262190A1 (en) 2012-01-19
AU2010262190B2 true AU2010262190B2 (en) 2013-01-31

Family

ID=42321053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010262190A Ceased AU2010262190B2 (en) 2009-06-19 2010-06-17 Novel phenylimidazole derivative as PDE10A enzyme inhibitor

Country Status (28)

Country Link
EP (1) EP2443105B1 (enExample)
JP (1) JP5768044B2 (enExample)
AR (1) AR077144A1 (enExample)
AU (1) AU2010262190B2 (enExample)
BR (1) BRPI1015983A2 (enExample)
CA (1) CA2765750A1 (enExample)
CR (1) CR20110654A (enExample)
CY (1) CY1115971T1 (enExample)
DK (1) DK2443105T3 (enExample)
DO (1) DOP2011000397A (enExample)
ES (1) ES2527216T3 (enExample)
GE (1) GEP20146100B (enExample)
GT (1) GT201100322A (enExample)
HR (1) HRP20141222T1 (enExample)
IL (1) IL216684A (enExample)
MA (1) MA33367B1 (enExample)
MX (1) MX2011013400A (enExample)
MY (1) MY156785A (enExample)
NZ (1) NZ597203A (enExample)
PL (1) PL2443105T3 (enExample)
PT (1) PT2443105E (enExample)
SG (1) SG176680A1 (enExample)
SI (1) SI2443105T1 (enExample)
SM (1) SMT201500003B (enExample)
TW (1) TW201100430A (enExample)
UA (1) UA106378C2 (enExample)
WO (1) WO2010145668A1 (enExample)
ZA (1) ZA201109271B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2013034758A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
WO2013034755A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
BR112020013743A2 (pt) * 2018-11-06 2020-12-01 H. Lundbeck A/S hemiadipato de 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina
WO2020094592A1 (en) * 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003129A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
WO2005082883A2 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2006070284A1 (en) * 2004-12-31 2006-07-06 Pfizer Products Inc. Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2004024705A1 (ja) 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited ５員複素環化合物
AU2003288352A1 (en) 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
EP1641457B1 (en) 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
BRPI0511854A (pt) 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2578996A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003129A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
WO2005082883A2 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2006070284A1 (en) * 2004-12-31 2006-07-06 Pfizer Products Inc. Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kehler, J. et al., Expert Opinion on Therapeutic Patents, 2007, vol. 17(2), 147-158 *

Also Published As

Publication number Publication date
CA2765750A1 (en) 2010-12-23
ES2527216T3 (es) 2015-01-21
HRP20141222T1 (hr) 2015-02-27
WO2010145668A1 (en) 2010-12-23
AU2010262190A1 (en) 2012-01-19
SG176680A1 (en) 2012-01-30
AR077144A1 (es) 2011-08-03
MY156785A (en) 2016-03-31
CY1115971T1 (el) 2017-01-25
ZA201109271B (en) 2013-02-27
GT201100322A (es) 2014-02-06
IL216684A (en) 2016-03-31
MA33367B1 (fr) 2012-06-01
JP5768044B2 (ja) 2015-08-26
JP2012530086A (ja) 2012-11-29
SI2443105T1 (sl) 2015-02-27
GEP20146100B (en) 2014-05-27
UA106378C2 (ru) 2014-08-26
PL2443105T3 (pl) 2015-03-31
CR20110654A (es) 2012-03-09
EP2443105A1 (en) 2012-04-25
IL216684A0 (en) 2012-02-29
PT2443105E (pt) 2015-01-14
DOP2011000397A (es) 2012-07-15
TW201100430A (en) 2011-01-01
SMT201500003B (it) 2015-03-05
BRPI1015983A2 (pt) 2016-04-19
MX2011013400A (es) 2012-02-21
DK2443105T3 (en) 2015-01-12
EP2443105B1 (en) 2014-10-29
HK1171446A1 (en) 2013-03-28
NZ597203A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
US8841297B2 (en) Phenylimidazole derivative as PDE10A enzyme inhibitor
EP2443105B1 (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
US8501797B2 (en) (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives
EP2513107B1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
EP2513106B1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
US9018217B2 (en) Phenylimidazole derivatives as PDE10A enzyme inhibitors
WO2012000519A1 (en) Aryl- and heteroarylamid derivatives as pde10a enzyme inhibitor
HK1171446B (en) Phenylimidazole derivative as pde10a enzyme inhibitor
KR20120037408A (ko) Ｐｄｅ１０ａ 효소 저해제로서의 신규한 페닐이미다졸 유도체

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired